Theobromine

Theobromine

1. Identity: Chemical and Botanical Profile

1.1 Names and Classification

Theobromine, systematically named 3,7-dimethylxanthine, is a compound prepared from the dried, ripe seed of Theobroma cacao (Family Sterculiaceae) or is made synthetically. It is a flat molecule, a derivative of purine, and an isomer of theophylline. Despite its name, the compound contains no bromine — "theobromine" is derived from Theobroma, the name of the genus of the cacao tree, itself composed of the Greek roots theo ("god") and broma ("food"), meaning "food of the gods," with the suffix -ine given to alkaloids and other basic nitrogen-containing compounds. Its molecular formula is C₇H₈N₄O₂. It is also known by the synonym xantheose.

1.2 Physical Properties

Theobromine occurs as a white, crystalline powder with a bitter taste and sublimes at about 260°C. The base is slightly soluble in cold water or in alcohol. It is a white or colourless solid, but commercial samples can appear yellowish.

1.3 Discovery and Synthesis

The compound gets its name from the cacao tree genus Theobroma, but it is also found in tea leaves and kola nuts. A. Woskresensky discovered theobromine in cacao beans in 1841, and E. Fischer synthesized it in 1882.

1.4 Botanical Sources

Theobromine is the principal alkaloid of Theobroma cacao (the cacao plant). It is found in chocolate and several other foods, including tea (Camellia sinensis), some American hollies (yaupon and guayusa), and the kola nut. Theobromine has been reported in cacao husks and beans at 0.7–1.2% and 1.5–3% (15–30 g/kg), at 20 mg/kg in green coffee beans, at 0.15–0.20% in manufactured tea, and at approximately 0.3% in dried maté.

Cocoa beans naturally contain approximately 1% theobromine. There are approximately 60 milligrams of theobromine in 28 grams (1 oz) of milk chocolate, while the same amount of dark chocolate contains about 200 milligrams. Dark chocolate contains the largest amount of theobromine per serving of any type of eating chocolate; concentrations vary widely (0.36–0.63%) owing to the initial large difference in the theobromine content in chocolate liquors, and one 1-oz bar of dark chocolate was found to contain 130 mg theobromine while one 1-oz bar of milk chocolate contained 44 mg theobromine. Mean theobromine concentrations in cocoa and related products include: cocoa powder at 2,060 mg per 100 g, cocoa beverages at 266 mg per 100 g, chocolate toppings at 195 mg per 100 g, chocolate bakery products at 147 mg per 100 g, cocoa cereals at 69.5 mg per 100 g, and chocolate ice creams at 62.1 mg per 100 g.

Theobromine can also be found in small amounts in the kola nut (1.0–2.5%), the guarana berry, and the tea plant. Cacao has a unique chemical composition of more than 500 different compounds, including members of the methylxanthine class (primarily theobromine, with a lower concentration of caffeine). Theobromine is used as a marker of cacao in organic residue studies of ceramics from Mesoamerica because T. cacao is the only Mesoamerican plant that contains theobromine as the primary methylxanthine.

1.5 Commercial Forms and Preparations

Theobromine is available commercially as a purified white crystalline powder used in dietary supplements, typically in oral capsule or tablet form. It is also prepared synthetically from Theobroma cacao seed. In industry, theobromine is used as an additive and precursor to some cosmetics. It is also consumed naturally through foods—most prominently chocolate, cocoa-based beverages, and tea. In the human liver, caffeine is metabolized by enzymes into approximately 10% theobromine, 4% theophylline, and 80% paraxanthine, meaning dietary caffeine is itself a secondary source of theobromine in the body.

---

2. Traditional and Historical Use

2.1 Pre-Columbian South America

Cacao (Theobroma cacao L.) is an important economic crop whose domestication history is still being studied. Traditionally, cacao was thought to have been first domesticated in Mesoamerica; however, genomic research shows that T. cacao's greatest diversity lies in the upper Amazon region of northwest South America. Three independent lines of archaeological evidence — cacao starch grains, absorbed theobromine residues, and ancient DNA — dating from approximately 5,300 years ago were recovered from the Santa Ana-La Florida (SALF) site in southeast Ecuador. These findings constitute the earliest evidence of T. cacao use in the Americas and the first unequivocal archaeological example of its pre-Columbian use in South America, revealing the upper Amazon region as the oldest centre of cacao domestication yet identified.

2.2 Olmec and Mesoamerican Cultures

Cacao cultivation in Mesoamerica dates back to the Early Formative period (2000–1000 BC). The Olmec culture was probably the first to domesticate it and to create the complex process for transforming cacao into chocolate. In a large collection of Olmec pottery found at the San Lorenzo site, traces of the alkaloid theobromine prove that the Olmecs had cacao-based beverages.

Chemical analyses of residues extracted from pottery vessels from Puerto Escondido in what is now Honduras show that cacao beverages were being made there before 1000 BCE. The famous chocolate beverage served on special occasions in later Mesoamerica, especially by elites, was made from cacao seeds. The earliest cacao beverages consumed at Puerto Escondido were likely produced by fermenting the sweet pulp surrounding the seeds.

Beverages produced from Theobroma spp. were integral to virtually all social and ritual occasions among the Aztecs and their contemporaries, and cacao was in consequence one of the most valued commodities in 16th-century Mesoamerica. The distinctive Mesoamerican style of cacao preparation involved fermenting cacao seeds (or "beans"), drying them, optionally toasting them, grinding them, and mixing them with water in a thick drink.

2.3 Maya Use

In recent decades, studies of cacao residues from ancient ceramics have employed methylxanthine biomarkers — caffeine, theobromine, and theophylline — ushering in a new means of addressing the use of cacao in prehistory. Chemical residue analyses have focused on vessels from elite Maya burials and caches, suggesting cacao represented wealth and power. Cacao residues have been documented in special vessels from the Late Preclassic, circa 300 BCE, identified in a famous Early Classic vessel from Rio Azul, and recognized in Late Classic vases.

Results from a PNAS study (2022) show that cacao was culturally significant and widespread, found in both civic and residential units regardless of size and location. Cacao, known as "the money that grew on trees," was brought to the world stage by Mesoamericans and the Maya. The historical background and prehistory of cacao, particularly for the Maya, has been imbued with ceremony and luxury. Studies of glamorous drinking vases, prominent among Late Classic Maya (600 to 900 CE) ceramic vessels, highlight imagery of gift giving, ritual, royal prestige, and control.

2.4 Colonial Period and Early Medical Use

Spanish armies that invaded South and Central America in the sixteenth century used chocolate as a source of energy. Cacao-based preparations were subsequently introduced to Europe, where chocolate beverages became fashionable in royal courts during the 17th century. The pure compound has relatively few uses; however, most of them are medical. It has been used as a diuretic — a compound that increases the rate at which liquids are eliminated from the body — and as a mild stimulant.

---

3. Key Constituents and Mechanisms of Action

3.1 Chemical Class

Theobromine (3,7-dimethylxanthine) is the principal alkaloid in Theobroma cacao and other plants. It is used as a bronchodilator and as a vasodilator. Theobromine is a diuretic and a smooth muscle relaxant. It has little stimulant action on the central nervous system.

3.2 Primary Mechanisms of Action

Theobromine acts as a non-selective antagonist of adenosine receptors, operates as a competitive and non-selective inhibitor of phosphodiesterases, and disrupts the activity of poly(ADP-ribose) polymerase 1 to exert its physiological functions.

Adenosine receptor antagonism is considered the primary mechanism at pharmacologically relevant concentrations. Current concepts about the mechanisms underlying the therapeutic effects of dietary methylxanthines (caffeine, theophylline, and theobromine) favor their actions as antagonists of adenosine receptors, and attribute their other possible modes of action — namely those associated with translocation of intracellular calcium, inhibition of phosphodiesterase (PDE) activity, or release of catecholamines — to high (near-toxic) doses.

At the neuronal level, using electrophysiological recordings in mouse hippocampal synapses, theobromine (30 μM) facilitated synaptic transmission while decreasing the magnitude of long-term potentiation (LTP), with both effects being blunted by adenosine deaminase. The pharmacological blockade of A1R eliminated the theobromine-dependent facilitation of synaptic transmission, whereas the A2AR antagonist and genetic deletion of A2AR abrogated the theobromine-induced impairment of LTP.

Phosphodiesterase (PDE) inhibition is also operative, particularly at higher concentrations. Theobromine functions as an inhibitor of phosphodiesterase enzymes (PDEs). By inhibiting these enzymes, theobromine increases cyclic adenosine monophosphate (cAMP) levels in cells, which in turn leads to various physiological effects such as vasodilation and smooth muscle relaxation.

Theobromine, a metabolite of caffeine, is processed in the liver into xanthine and methyluric acid, peaks in the blood 2–3 hours after ingestion due to its fat solubility, and primarily acts by inhibiting adenosine receptors with minor phosphodiesterase inhibition.

3.3 Cardiovascular Effects

Theobromine is a mild heart stimulant and bronchodilator in humans with limited central nervous system effects. The main sites of action of xanthine compounds in the body are the central nervous system, cardiovascular system, kidneys, smooth muscle, and skeletal musculature. Theobromine in particular acts as a smooth muscle relaxant, coronary artery dilator, diuretic, and cardiac stimulant.

3.4 Relationship to Caffeine Metabolism

As a metabolite of caffeine in mammals, theobromine shares similar pharmacological effects, primarily attributed to its structural resemblance to adenosine. In the human liver, caffeine is metabolized by enzymes into approximately 10% theobromine, 4% theophylline, and 80% paraxanthine.

---

4. Pharmacokinetics

Chocolate is derived from the roasted seeds of Theobroma cacao, and the main toxic components are the methylxanthine alkaloids theobromine and caffeine. Humans can easily digest and excrete methylxanthines, the half-life of theobromine in humans being 2–3 hours (though some sources report longer values: in humans, the theobromine plasma half-life has been reported as 6.1–10 hours, reflecting variability across formulations and populations).

Theobromine is a highly lipophilic molecule, rapidly absorbed through the gastrointestinal tract, penetrates the blood-brain barrier, and exerts psychostimulant effects without any dependence.

The route of administration and formulation significantly affects absorption speed. The maximal plasma level of theobromine was reached three hours after the administration of a capsule, while using a chocolate-based formulation the absorption was much quicker, reaching the maximal plasma concentration two hours after treatment.

The half-life of theobromine in humans is 2–3 hours, whereas absorption in dogs is relatively slow, with metabolism in the liver and extrahepatic recirculation before excretion in the urine, which results in a half-life in dogs of approximately 18 hours.

---

5. Scientific Evidence by Area of Use

5.1 Respiratory System: Cough Suppression (Antitussive Action)

This is one of the most robustly studied areas for theobromine in humans.

A key early study from 2005 (Usmani et al., published in The FASEB Journal) investigated theobromine's effects on cough. The researchers demonstrated that theobromine directly inhibits capsaicin-induced sensory nerve depolarization of guinea pig and human vagus nerve, suggestive of an inhibitory effect on afferent nerve activation. These data indicate the actions of theobromine appear to be peripherally mediated. The authors concluded that theobromine is a novel and promising treatment that may form the basis for a new class of antitussive drugs.

This double-blind placebo-controlled study was complemented with in vitro studies using human vagus nerve preparations in which theobromine inhibited the depolarization effect of capsaicin; theobromine thus appears to suppress cough by inhibiting the activation of afferent nerves.

In the human trial component, theobromine inhibited cough at concentrations that do not have central side effects in humans, which is described as unique in the field of cough therapy.

A larger Phase III randomized controlled trial (Morice et al., published in the Journal of Thoracic Disease, 2017) examined the compound BC1036 (a theobromine formulation): this was a randomised, multicentre, double-blind, placebo-controlled, parallel-group study in 289 subjects with persistent cough. Subjects received BC1036 or placebo twice daily for 14 days. The primary endpoint comprised cough-related quality of life assessed using the validated Leicester Cough Questionnaire (LCQ) at Day 14. Theobromine has been suggested as a promising therapy for the treatment of persistent cough. It has a rapid onset, long duration of activity (greater than 4 hours), and is substantially more effective than caffeine in inhibiting cough induced by citric acid in the guinea pig model.

Preclinical and clinical studies have suggested that both theophylline and theobromine act as antitussive agents in several preclinical studies and in patients with a range of clinical conditions.

Evidence strength: Preliminary to moderate for cough suppression. There is human clinical evidence (a placebo-controlled trial in 289 subjects and smaller mechanistic human studies), but theobromine-based formulations have not yet achieved widespread regulatory approval as antitussives. The peripheral mechanism (afferent nerve inhibition) is distinct from central opioid-based cough suppressants.

5.2 Respiratory System: Bronchodilation

Theobromine has a historical clinical use as a bronchodilator. The bronchodilator effect of a 10 mg/kg dose of theobromine was compared with that of 5 mg/kg of theophylline in young patients with asthma. Bronchodilation, as assessed by forced vital capacity, forced expiratory volume in the first second, forced expiratory flows at 25%, 50%, and 75% of vital capacity, and percent of FEV₁/FVC did not differ significantly between the two drugs. After each drug, bronchodilation peaked at 2 hours and lasted for 6 hours, although it was not always statistically significant for theobromine.

Theobromine has some pharmacological effects, although these activities are considerably weaker than those of theophylline and/or caffeine.

Evidence strength: Weak to moderate. Clinical studies from the 1980s demonstrate bronchodilatory activity in asthma patients, but theobromine's potency as a bronchodilator is substantially lower than theophylline, explaining why it disappeared from clinical use in this indication.

5.3 Cardiovascular System: HDL Cholesterol and Lipid Profile

This area has received considerable recent clinical attention.

A key randomized controlled trial (Neufingerl et al., 2013, published in the American Journal of Clinical Nutrition) assessed whether theobromine raises HDL-cholesterol: the study had a 2-center, double-blind, randomized, placebo-controlled, full factorial parallel design. After a 2-week run-in period, 152 healthy men and women (aged 40–70 years) were randomly allocated to consume one 200-mL drink per day for 4 weeks containing either cocoa (naturally providing 150 mg theobromine and 325 mg flavonoids), 850 mg pure theobromine, cocoa plus added theobromine (1,000 mg theobromine and 325 mg flavonoids), or placebo. There was a significant main effect of theobromine (P < 0.0001) but not cocoa on HDL-cholesterol, and theobromine increased HDL-cholesterol concentrations by 0.16 mmol/L. The lack of significant cocoa and interaction effects suggested that theobromine may be the main ingredient responsible for the HDL cholesterol-raising effect.

The results of clinical trial NCT01481389 suggest that theobromine, but not flavonoids, is responsible for the increase in HDL levels in individuals taking cocoa products.

A further randomized controlled trial in patients with metabolic syndrome found: theobromine supplementation along with a low-calorie diet had favorable effects on waist circumference, LDL-c/HDL-c ratio, TG/HDL-c ratio, TC/HDL-c ratio, and serum level of HDL-c in overweight and obese subjects with metabolic syndrome. However, there were no significant differences regarding body weight, BMI, hip circumference, hip-to-waist ratio, systolic and diastolic blood pressure, fasting levels of total cholesterol, triacylglycerol, LDL-c, fasting blood glucose, insulin, or insulin resistance markers between the two groups.

A systematic review (published in Phytotherapy Research, 2023) that examined 19 studies noted: in vitro studies showed improving effects of theobromine on inflammatory markers; of four animal studies assessing the effect of theobromine on inflammatory markers, two reported favorable effects; among five animal studies assessing the effects of theobromine on lipid profile, three reported improving effects on either triglyceride, total cholesterol, low- or high-density lipoprotein cholesterol; of the three human studies, two revealed that theobromine had improving effects on lipid profile.

In a randomized, double-blind crossover study, thirty overweight and fourteen obese healthy men and women participated. Participants consumed 500 mg per day of theobromine or placebo for 4 weeks to investigate effects on HDL-mediated cholesterol efflux.

A randomized clinical trial (2025) examined theobromine's effects on HDL subclasses in metabolic syndrome: the study aimed to examine the effects of a 12-week intake of pure theobromine in combination with a low-calorie diet on serum levels of HDL-c2, HDL-c3, the HDL-c2/HDL-c3 ratio, and gene expression of PPAR-α and Sirt1 in overweight and obese adults with metabolic syndrome. In this randomized clinical trial, 80 participants with metabolic syndrome were randomly allocated to a 450 mg/day theobromine or placebo arm in combination with a low-calorie diet for 12 weeks.

Evidence strength: Moderate. The HDL-raising effect has been replicated in at least two controlled human trials. The 0.16 mmol/L increase in HDL-cholesterol from theobromine supplementation is a consistent finding. However, whether the lipid profile changes translate to reduced cardiovascular events is not yet established in long-term outcomes trials.

5.4 Neurological and Cognitive Effects

Nutritional qualities of cocoa have been acknowledged by several authors; a particular focus has been placed on its high content of flavanols. Other active components of cocoa are methylxanthines (caffeine and theobromine). Whereas the effects of caffeine are extensively researched, the same is not the case for theobromine. Considering animal studies, acute exposure to theobromine has a reduced and delayed nootropic effect with respect to caffeine, whereas both animal and human studies suggest a potential neuroprotective action of long-term assumption of theobromine through a reduction of Aβ amyloid pathology, which is commonly observed in Alzheimer's disease patients' brains.

A psychopharmacological study in 80 healthy participants tested oral theobromine doses of 250, 500, and 1,000 mg with an active control dose of caffeine (200 mg): caffeine had the expected effects on mood including feelings of alertness and cardiovascular parameters. Theobromine responses differed according to dose; it showed limited subjective effects at 250 mg and negative mood effects at higher doses. It also dose-dependently increased heart rate. The authors described it as the highest dose of theobromine studied in humans, concluding that theobromine at normal intake ranges may contribute to the positive effects of chocolate, but that at higher intakes, effects become negative.

A clinical trial (NCT01288547) examined theobromine (700 mg) and caffeine (120 mg) effects on mood and cognition in a double-blind, placebo-controlled, randomized crossover study in 24 healthy female subjects, using mood and cognition assessments with blood pressure as secondary parameters. The study's background stated that naturally occurring chocolate ingredients theobromine and caffeine have positive effects on mood, with the objective of assessing mood and cognition after consumption of capsules containing placebo, theobromine alone, caffeine alone, or theobromine and caffeine combined.

In animal and cellular research, theobromine has shown health benefits in several studies attributed to regulation of calcium homeostasis, phosphodiesterase, neurotransmission, and neurotrophins.

Evidence strength: Weak to preliminary for cognitive and neuroprotective effects in humans. The most robust data come from animal models and in vitro studies. The human cross-sectional and psychopharmacological data are consistent with modest effects, but well-powered longitudinal clinical trials in humans are lacking.

5.5 Diuretic Effects

High doses of theobromine can affect several physiological functions in the body, such as increasing the formation of urine in the kidney. Theobromine exhibits anti-inflammatory properties, facilitates adipocyte browning, and contributes to weight management by augmenting lipid metabolism. Moreover, theobromine displays the potential to prevent kidney stone formation by inhibiting uric acid crystallization and promoting diuresis.

Evidence strength: The diuretic effect is well-established pharmacologically, but clinical studies specifically measuring theobromine's diuretic activity at dietary exposure levels are limited.

5.6 Blood Pressure and Vascular Function

Despite successful efforts to lower atherogenic LDL-cholesterol concentrations, a substantial residual cardiovascular risk remains. An additive strategy to further lower this residual risk may be via raising HDL concentrations. Based on several studies, theobromine may be a promising candidate in this respect. Theobromine was shown to increase serum HDL-c concentrations by 0.16 mmol/L or 10% and apolipoprotein A-I levels by 8%. Whether this increase in HDL-c and apoA-I translates into improved vascular function had not been evaluated in a placebo-controlled human intervention study at the time this trial was registered (NCT02209025).

Evidence strength: The data on blood pressure effects from theobromine specifically (as opposed to whole cocoa or chocolate extracts) are preliminary. The vascular function studies are ongoing or have not yet been fully published.

---

6. Body Systems Associated with Theobromine

• Respiratory system: bronchodilation (smooth muscle relaxation of bronchial airways) and antitussive (cough suppression via peripheral afferent nerve inhibition)
• Cardiovascular system: mild cardiac stimulation, vasodilation, HDL-cholesterol elevation, coronary artery dilation
• Central nervous system: mild adenosine receptor antagonism, limited stimulant effects compared to caffeine; under investigation for neuroprotection and cognitive function
• Renal system: diuresis; preliminary evidence for inhibiting uric acid crystallization and potentially reducing kidney stone formation
• Metabolic: modest effects on lipid profile (HDL elevation, ratio improvements); preliminary data on adipocyte browning and lipid metabolism

---

7. Dosage Forms and Dosages Reported in Studies

The following dosages are drawn only from published clinical research cited above:

• 850 mg/day pure theobromine (one 200-mL drink daily for 4 weeks) in the Neufingerl et al. HDL-cholesterol RCT involving 152 healthy adults.
• 500 mg/day in a randomized, double-blind crossover study of 44 overweight/obese healthy men and women for 4 weeks, measuring cholesterol efflux and miRNA levels.
• 450 mg/day for 12 weeks in a randomized clinical trial in 80 participants with metabolic syndrome, in combination with a low-calorie diet.
• 250, 500, and 1,000 mg oral doses (single doses, within-subjects placebo-controlled design) in a psychopharmacological study of 80 healthy participants.
• 700 mg theobromine capsules (with and without 120 mg caffeine) in a double-blind, placebo-controlled crossover study in 24 healthy women over 4 weeks.
• 300 mg theobromine capsules were used in clinical trial NCT01416480 for antitussive effects in acute bronchitis.
• Based on dose-response data in guinea pigs and toxicological profiling, the proposed adult antitussive dose of theobromine was stated to vary between 200 and 500 mg, two or three times a day.
• In a study of 13 volunteers who consumed 200 mg theobromine orally three times during a 24-hour period, no clinical symptom or other pharmacological activity was observed. Ingestion of theobromine in sweet chocolate at a dose of 6 mg/kg body weight per day had no effect on clinical parameters in 12 human subjects.
• In a study in young asthma patients, a bronchodilator dose of 10 mg/kg was administered.

---

8. Safety Considerations and Interactions

8.1 Human Toxicity Profile

Among various methylxanthines, theobromine shows the lowest adverse effects with a greater therapeutic index. The toxic effects of theobromine (e.g., thymic atrophy, testicular atrophy, and decrease in fetal weight) in animals have been reported at very high doses, with an LD₅₀ of 950 mg/kg body weight in rats and 1,356 mg/kg body weight in mice. In humans, theobromine manifested very mild side effects (e.g., nausea, anorexia, sweating, headache) when given orally in large doses of 1–1.5 g per day.

It has been stated that "in large doses" theobromine may cause nausea and anorexia, and that daily intake of 50–100 g cocoa (0.8–1.5 g theobromine) by humans has been associated with sweating, trembling, and severe headache.

At high experimental doses in healthy human volunteers: theobromine showed limited subjective effects at 250 mg and negative mood effects at higher doses (500 and 1,000 mg), and dose-dependently increased heart rate.

8.2 Differential Species Toxicity

Chocolate's main toxic components are the methylxanthine alkaloids theobromine and caffeine. Humans can easily digest and excrete methylxanthines, the half-life of theobromine being 2–3 hours. However, absorption in dogs is slow, with metabolism in the liver and extrahepatic recirculation before excretion in the urine. The half-life of theobromine in dogs is about 18 hours. Theobromine primarily affects the central nervous, cardiovascular, and respiratory systems, and has a diuretic effect. The first signs of poisoning in dogs include vomiting, haematemesis, and polydipsia. Other signs may include hyperexcitability, hyperirritability, tachycardia, excessive panting, ataxia, and muscle twitching. Effects may progress to cardiac arrhythmias, seizures, and death. The lethal dose of theobromine is reported to be 100–500 mg/kg of body weight in dogs.

Cocoa powder and plain chocolate contain the highest concentrations (20 mg/g and 15 mg/g), milk chocolate has much less (2 mg/g), and white chocolate has the lowest concentration (0.1 mg/g). Thus, less than 100 g of plain chocolate may be fatal for a 10 kg dog.

8.3 Interactions with Other Methylxanthines

Critical review of toxic manifestations due to exposure to relatively large doses of caffeine and theophylline indicates that combined exposure may potentiate the toxic effects of either drug. Since theobromine is co-ingested with caffeine in most dietary sources (chocolate, tea, kola nut), and since caffeine is itself partially metabolized to theobromine in humans, the total methylxanthine load from combined sources should be considered.

8.4 Cardiovascular Interactions

Theobromine peaks in the blood 2–3 hours after ingestion due to its fat solubility and primarily acts by inhibiting adenosine receptors with minor phosphodiesterase inhibition. At the doses studied in clinical trials (250–1,000 mg), theobromine dose-dependently increased heart rate in healthy participants, which is relevant for individuals with pre-existing cardiac conditions.

8.5 Reproductive and Developmental Toxicity

Reproductive toxicity data from animal studies suggest that theobromine at high doses may affect fetal development. Toxic effects of theobromine (including thymic atrophy, testicular atrophy, and decrease in fetal weight) in animals have been reported at very high doses, with LD₅₀ values of 950 mg/kg body weight in rats and 1,356 mg/kg body weight in mice. Human-specific data on reproductive safety at supplemental doses are not well established in the current literature.

8.6 Regulatory Status

Theobromine is consumed widely as a naturally occurring dietary constituent without specific regulatory restrictions in most jurisdictions. As a purified dietary supplement, it is sold in capsule and powder forms. It has not received marketing authorization as a pharmaceutical drug for any indication in major markets, though investigational trials for cough suppression have been conducted.

---

References

• Theobromine | C7H8N4O2 | CID 5429 — PubChem, NIH
• Theobromine — Coffee, Tea, Mate, Methylxanthines and Methylglyoxal, NCBI Bookshelf (IARC Monographs)
• Theobromine — ScienceDirect Topics (Pharmacognosy overview)
• Theobromine — Wikipedia (overview, sources, properties)
• Theobromine — American Chemical Society, Molecule of the Week
• Theobromine: Uses, Interactions, Mechanism of Action — DrugBank
• The use and domestication of Theobroma cacao during the mid-Holocene in the upper Amazon — Nature Ecology & Evolution (Zarrillo et al., 2018)
• Chemical and archaeological evidence for the earliest cacao beverages — PMC / PNAS (Henderson et al., 2007)
• New light on the use of Theobroma cacao by Late Classic Maya — PNAS (Ford et al., 2022)
• Evidence of cacao use in the Prehispanic American Southwest — PNAS (Crown et al., 2009)
• Theobromine Targets Adenosine Receptors to Control Hippocampal Neuronal Function and Damage — PMC / MDPI (Passos et al., 2022)
• Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines — PubMed (Dulloo et al., 1992)
• Health benefits and mechanisms of theobromine — Journal of Functional Foods / ScienceDirect (2024)
• Theobromine for the treatment of persistent cough: a randomised, multicentre, double-blind, placebo-controlled clinical trial — PMC / Journal of Thoracic Disease (Morice et al., 2017)
• Theobromine inhibits sensory nerve activation and cough — PubMed / FASEB Journal (Usmani et al., 2005)
• Effect of cocoa and theobromine consumption on serum HDL-cholesterol concentrations: a randomized controlled trial — PubMed / American Journal of Clinical Nutrition (Neufingerl et al., 2013)
• Theobromine supplementation in combination with a low-calorie diet improves cardiovascular risk factors in overweight and obese subjects with metabolic syndrome: a randomized controlled trial — PubMed (2023)
• Theobromine Does Not Affect Fasting and Postprandial HDL Cholesterol Efflux Capacity, While It Decreases Fasting miR-92a Levels in Humans — PubMed (2018)
• A comprehensive insight into the molecular effect of theobromine on cardiovascular-related risk factors: A systematic review — PubMed / Phytotherapy Research (2023)
• The bronchodilator effect and pharmacokinetics of theobromine in young patients with asthma — PubMed / Journal of Allergy and Clinical Immunology (Simons et al., 1985)
• Psychopharmacology of theobromine in healthy volunteers — PubMed (Mitchell et al., 2013)
• Exploring cocoa properties: is theobromine a cognitive modulator? — PubMed (Martínez-Pinilla et al., 2019)
• Theobromine Improves Working Memory by Activating the CaMKII/CREB/BDNF Pathway in Rats — PMC (Yoneda et al., 2019)
• Neuroprotective Effects of Theobromine in permanent bilateral common carotid artery occlusion rat model of cerebral hypoperfusion — PubMed (2022)
• Methylxanthines: toxicity to humans. 3. Theobromine, paraxanthine and the combined effects of methylxanthines — PubMed (Stavric, 1988)
• Chocolate poisoning — PMC / BMJ (2005)
• The relevance of theobromine for the beneficial effects of cocoa consumption — Frontiers in Pharmacology (Martínez-Pinilla et al., 2015)
• The Effect of Theobromine Supplementation on HDL-c Subclasses, HDL-c2/HDL-c3 Ratio, and Gene Expression of PPAR-α and Sirt1 in Subjects With Metabolic Syndrome — PMC / Food Science & Nutrition (2025)
• NCT01416480: Clinical Trial to Evaluate the Safety and Efficacy of Theobromine Capsule as an Antitussive in Acute Cough Patients — ClinicalTrials.gov
• NCT01288547: Effects of Theobromine and Caffeine on Mood, Cognition and Blood Pressure — ClinicalTrials.gov
• NCT02209025: Theobromine in Cardiovascular Disease — ICH GCP Clinical Trials Registry